Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 7/20 | 0.37 |
| ▸ | CTSK | P43235 | 7/20 | 0.37 |
| ▸ | HMGCR | P04035 | 1/20 | 0.35 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 4/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | TACR1 | P25103 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.31 |
| ▸ | CTSB | P07858 | 1/20 | 0.31 |
| ▸ | PTGES | O14684 | 1/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26418878 | 0.75 | CYP3A4 (0.40) | CTSSCTSKMBOAT4ARKCNH2 | |
| SCHEMBL26420846 | 0.70 | KDM4E (0.37) | CTSSCTSKHMGCRAR | |
| SCHEMBL23510582 | 0.69 | NR1I2 (0.37) | CTSSCTSKKCNH2 | |
| SCHEMBL24988667 | 0.69 | HMGCR (0.41) | HMGCRKCNH2 | |
| SCHEMBL28262846 | 0.68 | RIPK1 (0.38) | CTSSCTSKARRIPK1PTGES | |
| SCHEMBL26774063 | 0.68 | POLB (0.39) | PTGESALOX5PPARG | |
| SCHEMBL23059308 | 0.67 | CTSS (0.35) | CTSSCTSKKCNH2 | |
| SCHEMBL2336364 | 0.67 | MBOAT4 (0.42) | CTSSCTSKMBOAT4KCNH2TACR1 | |
| SCHEMBL29349713 | 0.67 | MBOAT4 (0.42) | CTSSCTSKMBOAT4KCNH2TACR1 | |
| SCHEMBL2563256 | 0.67 | CTSS (0.40) | CTSSCTSKMBOAT4RIPK1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230126662-A1 | SPIROCYCLIC PIPERIDINE MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230126662-A1 | SPIROCYCLIC PIPERIDINE MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | MC2R, MC1R, MC3R | CTSS 2848/4885CTSK 2563/4885HMGCR 2507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.